3.93
-0.01 (-0.25%)
| Penutupan Terdahulu | 3.94 |
| Buka | 3.95 |
| Jumlah Dagangan | 858,622 |
| Purata Dagangan (3B) | 650,518 |
| Modal Pasaran | 370,676,416 |
| Harga / Jualan (P/S) | 31.78 |
| Harga / Buku (P/B) | 2.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Keuntungan | 46.54% |
| Margin Operasi (TTM) | -32.78% |
| EPS Cair (TTM) | 2.11 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 340.14% |
| Nisbah Semasa (MRQ) | 3.70 |
| Aliran Tunai Operasi (OCF TTM) | -109.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -78.01 M |
| Pulangan Atas Aset (ROA TTM) | -58.61% |
| Pulangan Atas Ekuiti (ROE TTM) | 121.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | X4 Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 5.0 |
| Purata | 1.50 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.43% |
| % Dimiliki oleh Institusi | 55.70% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |